BonePub Date : 2025-10-04DOI: 10.1016/j.bone.2025.117676
Mengyuan Cai, Jinluan Chen, Jiawei Li, Katerina Trajanoska, Evert F S van Velsen, M Carola Zillikens
{"title":"Skin Advanced Glycation End Products (AGEs) are not associated with bone mineral density longitudinally: The Rotterdam Study.","authors":"Mengyuan Cai, Jinluan Chen, Jiawei Li, Katerina Trajanoska, Evert F S van Velsen, M Carola Zillikens","doi":"10.1016/j.bone.2025.117676","DOIUrl":"https://doi.org/10.1016/j.bone.2025.117676","url":null,"abstract":"<p><strong>Background: </strong>Advanced glycation end products (AGEs), formed through non-enzymatic glycation of, e.g., proteins in collagen have been associated with prevalent fractures, but their relation with bone mineral density (BMD) and trabecular bone score (TBS) is unclear.</p><p><strong>Objectives: </strong>To assess the association of skin AGEs with BMD and TBS changes over time.</p><p><strong>Methods: </strong>In the Rotterdam Study, skin AGEs were assessed as skin autofluorescence (SAF) using the AGE Reader®. Total body (TB), femoral neck (FN) and lumbar spine (LS) BMD were assessed using dual-energy X-ray absorptiometry (DXA). SAF was analyzed with baseline and follow-up BMD and TBS, employing a linear mixed effects model adjusted for clinical and lifestyle confounders, with interaction analysis for sex, prevalent type 2 diabetes mellitus (T2DM), chronic kidney disease, and bisphosphonate use.</p><p><strong>Results: </strong>Longitudinal analyses between SAF and TB BMD were performed in 2553 participants (mean follow-up time 4.9 years), and between SAF and LS BMD, FN BMD and TBS in 851 participants (mean follow-up 5.6 years). SAF was not associated with BMD nor with TBS changes over time. Significant interactions were observed with sex (TB and FN BMD) and with diabetes (FN BMD), but stratified analysis revealed no significant associations.</p><p><strong>Conclusion: </strong>We did not observe a longitudinal association between SAF and BMD at multiple sites or TBS, which is consistent with our earlier findings that associations of SAF with prevalent fractures were not explained by BMD or TBS. Other aspects of bone quality or muscle characteristics including fall risk may be involved.</p>","PeriodicalId":93913,"journal":{"name":"Bone","volume":" ","pages":"117676"},"PeriodicalIF":3.6,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BonePub Date : 2025-10-03DOI: 10.1016/j.bone.2025.117664
Mengshu Cao, Fang Pang, Xueyou Duan, Lijun Sun, Xiushan Fan, Liang Tang, Dean Ta
{"title":"Piezo1-mediated mechanotransduction regulates diabetic osteoporosis and hyperglycemia via low-intensity pulsed ultrasound.","authors":"Mengshu Cao, Fang Pang, Xueyou Duan, Lijun Sun, Xiushan Fan, Liang Tang, Dean Ta","doi":"10.1016/j.bone.2025.117664","DOIUrl":"10.1016/j.bone.2025.117664","url":null,"abstract":"<p><p>This study investigates the effects and mechanism by which low-intensity pulsed ultrasound (LIPUS) regulates osteoporosis and hyperglycemia in mice with type 1 diabetes mellitus (T1DM). The mice were randomly divided into four groups: normal control (NC), T1DM mice (DM), T1DM mice treated with insulin (DM + INS), and T1DM mice treated with LIPUS (DM + LIPUS). The DM + INS group served as a positive control for the study. The DM + LIPUS group received LIPUS treatment (80 mW cm<sup>-2</sup>, 20 min daily) on the quadriceps femoris for 6 weeks. The results show that LIPUS improves the mechanical properties, morphological characteristics, and bone microstructure and alleviate hyperglycemia in the T1DM mice. In addition, knockout of Piezo1 using CRISPR-Cas9 was performed in MC3T3-E1 cells (Piezo1<sup>-/-</sup>) to verify the role of LIPUS during treatment. The cell experiments showed that LIPUS improved proliferation, osteogenic differentiation capabilities, and cytoskeletal morphology, while significantly reducing the extracellular glucose level of MC3T3-E1 cells in a high glucose medium. All these results indicate that Piezo1-mediated mechanotransduction is closely related to the alleviation of osteoporosis and hyperglycemia in T1DM mice treated with LIPUS. LIPUS showed comparable efficacy to insulin in reducing the severity of osteoporosis and lowering hyperglycemia in T1DM mice. This therapy effectively alleviated symptoms (including osteoporosis and hyperglycemia) in T1DM mice without insulin injections. These findings suggest that LIPUS therapy could serve as an adjunct method to conventional diabetes treatment in T1DM.</p>","PeriodicalId":93913,"journal":{"name":"Bone","volume":" ","pages":"117664"},"PeriodicalIF":3.6,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BonePub Date : 2025-10-03DOI: 10.1016/j.bone.2025.117665
Carlos A Urrego, Benjamin S Sexton, David H Kohn
{"title":"Decreased bone strength in skeletally mature female mice with T2D is associated with changes in OLCN and spatially compromised architecture.","authors":"Carlos A Urrego, Benjamin S Sexton, David H Kohn","doi":"10.1016/j.bone.2025.117665","DOIUrl":"https://doi.org/10.1016/j.bone.2025.117665","url":null,"abstract":"<p><p>Women with Type-2 diabetes (T2D) have a higher incidence of fractures and associated mortality compared to men. However, most animal models for studying diabetes-induced bone effects use males and the impact of T2D on bone quality in skeletally mature females remains unknown. We developed a mouse model to determine the effect of T2D on female bone quality. T2D was induced in 16-week-old female C57BL/6J mice using a High-Fat Diet and Streptozotocin (HFD + STZ), controls received a Low-Fat Diet and sham injections (LFD + VEH). The diabetic group displayed hyperglycemia, hypoinsulinemia, and increased body fat. T2D altered bone architecture spatially, the T2D group displayed decreased cortical and trabecular bone volume (BV) and total volume (TV) with varying magnitude at specific locations compared to the control. T2D also reduced bone yield and ultimate loads under four-point bending, without affecting tissue-level properties. Moreover, changes in TV with T2D explained up to 70 % of the variance in bone strength, suggesting that the weakening effect of T2D on female bone strength is architecture-driven. Compromised architecture with T2D was associated with changes in the Osteocyte Lacuno-Canalicular Network (OLCN). T2D decreased canalicular density, the total number of nodes and increased lacunae surface area. These changes in the OLCN with T2D explained up to 37 % of bone architecture variance. In summary, our novel T2D female mouse model displayed a bone phenotype with compromised OLCN associated to impaired architecture, which led to decreased bone strength. These outcomes suggest that the effect of T2D on female bone strength is architecture-driven rather than material-driven.</p>","PeriodicalId":93913,"journal":{"name":"Bone","volume":" ","pages":"117665"},"PeriodicalIF":3.6,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A deep intronic PHEX variant in a large Danish family with hereditary hypophosphatemia and a milder skeletal, but more severe dental phenotype.","authors":"Jenny Blechingberg, Kristian Alsbjerg Skipper, Signe Sparre Beck-Nielsen, Pernille Axél Gregersen","doi":"10.1016/j.bone.2025.117666","DOIUrl":"https://doi.org/10.1016/j.bone.2025.117666","url":null,"abstract":"<p><p>Hereditary hypophosphatemia (HH) are rare diseases, characterized by excessive renal phosphate wasting, rickets and osteomalacia in growing children, and osteomalacia in adults. There are several types of HH caused by pathogenic variants in a number of different genes. We present a large Danish family consisting of 19 family members with clinically and biochemically hypophosphatamia caused by a previously unreported deep intronic splice variant in PHEX: c.1080-687 A > G (p.?). The affected family members displayed a milder HH phenotype compared with a larger group of individuals with other disease causing PHEX variants. We were able to genetically confirm a diagnosis of X-linked hypophosphatemia (XLH) by genome sequencing intron analysis and in vitro analysis consisting of an exon trapping assay. Our findings emphasize the phenotypic variability of XLH, where this family in general displays a milder phenotype. Furthermore, our findings demonstrate that XLH can be caused by intron variants in PHEX.</p>","PeriodicalId":93913,"journal":{"name":"Bone","volume":" ","pages":"117666"},"PeriodicalIF":3.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145226488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BonePub Date : 2025-09-25DOI: 10.1016/j.bone.2025.117646
Lyan Abdul Wadood, Victoria McHugh, Kristin K Clemens, Mary E Jenkins, Jeffrey D Holmes, Jamie L Fleet
{"title":"Management of osteoporosis in Parkinson's disease: A scoping review.","authors":"Lyan Abdul Wadood, Victoria McHugh, Kristin K Clemens, Mary E Jenkins, Jeffrey D Holmes, Jamie L Fleet","doi":"10.1016/j.bone.2025.117646","DOIUrl":"https://doi.org/10.1016/j.bone.2025.117646","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's Disease (PD) is a progressive neurodegenerative disorder that primarily affects the dopaminergic neurons in the basal ganglia. It leads to a range of motor symptoms such as tremors, bradykinesia, rigidity, and gait instability. A significant, but often overlooked, sequela of PD is osteoporosis, which contributes to a higher incidence of fractures. This risk is exacerbated by both PD itself as well as the medications used to manage PD. Despite the heightened risk of fragility fractures, osteoporosis in PD is frequently under-recognized and inadequately managed.</p><p><strong>Objective: </strong>This review aimed to explore the current literature on osteoporosis management strategies specifically for individuals with PD.</p><p><strong>Methods: </strong>MEDLINE, Scopus, and EMBASE were searched from database inception to August 10, 2025.</p><p><strong>Results: </strong>Following a two-stage review process conducted by two independent reviewers, 18 relevant articles were identified. Of these, 17 were review articles and one was an interventional study. The literature most commonly identified lifestyle modifications, pharmacological treatments, and surgical interventions as management strategies for osteoporosis in PD. However, most of the recommendations were based on research conducted in the general population, raising concerns about their effectiveness for individuals with PD, who may have unique clinical needs.</p><p><strong>Conclusions: </strong>We note a significant gap in research focused on osteoporosis management in PD patients. Research efforts should prioritize developing tailored strategies to manage osteoporosis in individuals with PD.</p>","PeriodicalId":93913,"journal":{"name":"Bone","volume":" ","pages":"117646"},"PeriodicalIF":3.6,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BonePub Date : 2025-09-11DOI: 10.1016/j.bone.2025.117641
Giulia Montagna, Stephanie Lee, Austin Baacke, Matthew L Warman, Christina M Jacobsen
{"title":"Enhancing Wnt signaling lowers fracture incidence in a severe mouse model of Osteogenesis Imperfecta.","authors":"Giulia Montagna, Stephanie Lee, Austin Baacke, Matthew L Warman, Christina M Jacobsen","doi":"10.1016/j.bone.2025.117641","DOIUrl":"10.1016/j.bone.2025.117641","url":null,"abstract":"<p><p>Increased fracture is a hallmark feature of the skeletal disorder Osteogenesis Imperfecta (OI). A neutralizing antibody against sclerostin, an endogenous Wnt signaling inhibitor, has been FDA-approved for osteoporosis and is now in clinical trials for OI. This anti-sclerostin antibody increased bone mass and skeletal strength in several preclinical models of OI. Because in vivo fracture incidence is the primary outcome measure in human OI clinical trials, we examined the effect of enhancing Wnt signaling in a preclinical mouse model of severe, autosomal dominant OI (the Col1a1<sup>Aga2/+</sup> mouse). We genetically enhanced Wnt signaling using the Lrp5<sup>A214V</sup> allele, which makes the Wnt co-receptor LRP5 resistant to sclerostin inhibition. By crossing Col1a1<sup>Aga2/+</sup> sires with Lrp5<sup>A214V/+</sup> dams, we generated pups with OI alone and pups with OI plus enhanced Wnt signaling. We radiographically examined these animals for fractures at 5, 9, and 13 weeks of age and also measured their mobility using a Holeboard assay. We found that enhanced Wnt signaling significantly reduced fracture numbers in this OI model by 30 % at each age but did not significantly affect mobility. These data indicate that an enhanced Wnt signaling decreases fracture incidence in a preclinical model of severe OI and suggest that lower fracture rates could be achieved by administering anti-sclerostin antibodies to OI patients.</p>","PeriodicalId":93913,"journal":{"name":"Bone","volume":" ","pages":"117641"},"PeriodicalIF":3.6,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BonePub Date : 2024-05-01DOI: 10.1016/j.bone.2024.117124
Junqing Miao, Xiaole Kong, Jingzhi Wang
{"title":"Letter to the editor concerning 'Impact of diabetes on the risk of subsequent fractures in 92,600 patients with an incident hip fracture: A Danish nationwide cohort study 2004-2018'.","authors":"Junqing Miao, Xiaole Kong, Jingzhi Wang","doi":"10.1016/j.bone.2024.117124","DOIUrl":"https://doi.org/10.1016/j.bone.2024.117124","url":null,"abstract":"","PeriodicalId":93913,"journal":{"name":"Bone","volume":"38 23","pages":"117124"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141045049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BonePub Date : 2024-05-01DOI: 10.1016/j.bone.2024.117125
Josephine T Tauer, Tobias Thiele, Catherine Julien, Lior Ofer, P. Zaslansky, Ron Shahar, Bettina M. Willie
{"title":"Swim training induces distinct osseous gene expression pattern in anosteocytic and osteocytic teleost fish.","authors":"Josephine T Tauer, Tobias Thiele, Catherine Julien, Lior Ofer, P. Zaslansky, Ron Shahar, Bettina M. Willie","doi":"10.1016/j.bone.2024.117125","DOIUrl":"https://doi.org/10.1016/j.bone.2024.117125","url":null,"abstract":"","PeriodicalId":93913,"journal":{"name":"Bone","volume":"210 S650","pages":"117125"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141040215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BonePub Date : 2024-03-01Epub Date: 2024-03-31DOI: 10.5187/jast.2023.e52
Olivier Munezero, Sungbo Cho, In Ho Kim
{"title":"The effects of synbiotics-glyconutrients on growth performance, nutrient digestibility, gas emission, meat quality, and fatty acid profile of finishing pigs.","authors":"Olivier Munezero, Sungbo Cho, In Ho Kim","doi":"10.5187/jast.2023.e52","DOIUrl":"10.5187/jast.2023.e52","url":null,"abstract":"<p><p>Glyconutrients help in the body's cell communication. Glyconutrients and synbiotics are promising options for improving immune function. Therefore, we hypothesized that combining synbiotics and glyconutrients will enhance pig nutrient utilization. 150 pigs (Landrace × Yorkshire × Duroc), initially weighing 58.85 ± 3.30 kg of live body weight (BW) were utilized to determine the effects of synbiotics-glyconutrients (SGN) on the pigs' performance, feed efficiency, gas emission, pork traits, and composition of fatty acids. The pigs were matched by BW and sex and chosen at random to 1 of 3 diet treatments: control = Basal diet; TRT1 = Basal diet + SGN 0.15%; TRT2 = Basal diet + SGN 0.30%%. The trials were conducted in two phases (weeks 1-5 and weeks 5-10). The average daily gain was increased in pigs fed a basal diet with SGN (<i>p</i> = 0.036) in weeks 5-10. However, the apparent total tract digestibility of dry matter, nitrogen, and gross energy did not differ among the treatments (<i>p</i> > 0.05). Dietary treatments had no effect on NH<sub>3</sub>, H<sub>2</sub>S, methyl mercaptans, acetic acids, and CO<sub>2</sub> emissions (<i>p</i> > 0.05). Improvement in drip loss on day 7 (<i>p</i> = 0.053) and tendency in the cooking loss were observed (<i>p</i> = 0.070) in a group fed basal diets and SGN at 0.30% inclusion level. The group supplemented with 0.30% of SGN had higher levels of palmitoleic acid (C16:1), margaric acid (C17:0), omega-3 fatty acid, omega-6 fatty acid, and ω-6: ω-3 ratio (<i>p</i> = 0.034, 0.020, 0.025, 0.007, and 0.003, respectively) in the fat of finishing pigs. Furthermore, group supplemented with 0.30% of SGN improved margaric acid (C17:0), linoleic acid (C18:2n6c), arachidic acid (C20:0), omega 6 fatty acid, omega-6 to omega-3 ratio, unsaturated fatty acid, and monounsaturated fatty acid (p = 0.037, 0.05, 0.0142, 0.036, 0.033, 0.020, and 0.045, respectively) in the lean tissues of finishing pigs compared to pigs fed with the control diets. In conclusion, the combination of probiotics, prebiotics, and glyconutrients led to higher average daily gain, improved the quality of pork, and more favorable fatty acid composition. Therefore, these results contributed to a better understanding of the potential of SGN combinations as a feed additive for pigs.</p>","PeriodicalId":93913,"journal":{"name":"Bone","volume":"29 1","pages":"310-325"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11016742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78886618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}